Trailing-twelve-month (TTM) revenue is $410.98 Billion with a year-over-year growth of +8.84%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $103,150,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q3 FY2026Period ended 2025-12-31 | $106,158,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-04 |
| Q4 FY2026Period ended 2026-03-31 | $96,295,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q1 FY2027Period ended 2026-06-30 | $105,380,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $410,983,000,000 |
Current P/S: $102,967,759,440 market capitalization ÷ $410,983,000,000 TTM revenue = 0.25x.
Market capitalization source: FMP quote. Quote observed 2026-09-18T18:20:13.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q1 FY2027 (2026-06-30): $105.38B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-18T18:21:10.742Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-03-31 · USD | FY20222022-03-31 · USD | FY20232023-03-31 · USD | FY20242024-03-31 · USD | FY20252025-03-31 · USD | FY20262026-03-31 · USD |
|---|---|---|---|---|---|---|
| International Segment | $36.0B | $36.3B | $20.6B | $14.1B | $14.7B | N/A |
| Medical-Surgical Solutions Segment | $10.1B | $11.6B | $11.1B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20152015-03-31 · USD | FY20162016-03-31 · USD | FY20172017-03-31 · USD | FY20182018-03-31 · USD | FY20192019-03-31 · USD | FY20202020-03-31 · USD |
|---|---|---|---|---|---|---|
| International Segment | N/A | $32.6B | $34.1B | $38.4B | $38.0B | $38.3B |
| UNITED STATES | $142.8B | $158.3B | $164.4B |
$410.98B
$410.98 Billion
+8.84%
vs. $377.60B a year ago (TTM)
+10.88%
5 Year compound annual growth rate
1 Year
+8.84%
3 Year
+13.10%
5 Year
+10.88%
10 Year
+7.85%
15 Year
+8.89%
20 Year
+7.85%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $403.43B | +$44.38B | +12.36% |
| 2025 | $359.05B | +$50.10B | +16.22% |
| 2024 | $308.95B | +$32.24B | +11.65% |
| 2023 | $276.71B | +$12.74B | +4.83% |
| 2022 | $263.97B | +$25.74B | +10.80% |
| 2021 |
TTM Growth
+8.84%
3-Year CAGR
+13.10%
5-Year CAGR
+10.88%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-18T18:21:10.742Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2020-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $11.3B |
| $11.4B |
| $11.5B |
| North American Pharmaceutical Segment | N/A | N/A | N/A | N/A | N/A | $336.7B |
|---|
| Oncology And Multispecialty Segment | N/A | N/A | N/A | N/A | N/A | $48.4B |
|---|
| Prescription Technology Solutions | $2.9B | $3.9B | $4.4B | $4.8B | $5.2B | N/A |
|---|
| Prescription Technology Solutions Segment | N/A | N/A | N/A | N/A | N/A | $5.8B |
|---|
| Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment | N/A | N/A | N/A | N/A | N/A | $1.0B |
|---|
| U.S. Pharmaceutical Segment | $189.3B | $212.1B | $240.6B | $278.7B | $327.7B | N/A |
|---|
| $176.3B |
| $192.7B |
| $238.23B |
| +$7.18B |
| +3.11% |
| 2020 | $231.05B | +$16.73B | +7.81% |
| 2019 | $214.32B | +$5.96B | +2.86% |
| 2018 | $208.36B | +$9.82B | +4.95% |
| 2017 | $198.53B | +$7.65B | +4.01% |
